Phase II Study of UFT in Patients With Advanced Non-Small Cell Lung Cancer |
| |
Authors: | KEICHO, NAOTO SAIJO, NAGAHIRO SHINKAI, TETSU EGUCHI, KENJI SASAKI, YASUTSUNA TAMURA, TOMOHIDE SAKURAI, MASANORI SANO, TETSURO HOSHI, AKIO |
| |
Affiliation: | Department of Internal Medicine, National Cancer Center Hospital Tokyo *Pharmacology Division, National Cancer Center Research Institute Tokyo |
| |
Abstract: | A phase II study of UFT (a mixture of uracil and tegafur; molarratio of uracil to tegafur = 4) was undertaken in 21 patientswith advanced non-small cell lung cancer (NSCLC). UFT was administeredorally at a dose of 400 mg/m2 every day, for more than fourweeks. Of 16 adequately treated patients, one (6.3%) showed a partialresponse. Toxic effects included minimal myelosuppression, anorexia,nausea, vomiting and epigastralgia. Gastrointestinal toxicitywas well tolerated. Considering the poor response and mild toxicity,a further phase II study of higher-dose UFT is necessary forpatients without prior therapy. |
| |
Keywords: | |
本文献已被 Oxford 等数据库收录! |
|